Aldeyra Therapeutics, Inc (NASDAQ:ALDX) Shares Purchased by Jacobs Levy Equity Management Inc.

Jacobs Levy Equity Management Inc. grew its holdings in shares of Aldeyra Therapeutics, Inc (NASDAQ:ALDX - Free Report) by 163.4% in the 3rd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 476,949 shares of the biotechnology company's stock after purchasing an additional 295,864 shares during the quarter. Jacobs Levy Equity Management Inc. owned approximately 0.80% of Aldeyra Therapeutics worth $2,571,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds and other institutional investors have also recently made changes to their positions in the business. Price T Rowe Associates Inc. MD lifted its position in Aldeyra Therapeutics by 7.7% during the first quarter. Price T Rowe Associates Inc. MD now owns 48,273 shares of the biotechnology company's stock valued at $158,000 after purchasing an additional 3,446 shares in the last quarter. SG Americas Securities LLC purchased a new position in shares of Aldeyra Therapeutics during the 2nd quarter valued at about $38,000. Diversified Trust Co bought a new position in shares of Aldeyra Therapeutics during the 2nd quarter valued at approximately $41,000. Hennion & Walsh Asset Management Inc. increased its holdings in Aldeyra Therapeutics by 8.6% in the 2nd quarter. Hennion & Walsh Asset Management Inc. now owns 88,122 shares of the biotechnology company's stock worth $292,000 after acquiring an additional 6,944 shares in the last quarter. Finally, Bank of New York Mellon Corp raised its stake in Aldeyra Therapeutics by 21.7% during the 2nd quarter. Bank of New York Mellon Corp now owns 195,722 shares of the biotechnology company's stock worth $648,000 after acquiring an additional 34,885 shares during the period. Hedge funds and other institutional investors own 59.71% of the company's stock.

Aldeyra Therapeutics Trading Up 5.5 %

Shares of ALDX traded up $0.27 during mid-day trading on Friday, reaching $5.22. The stock had a trading volume of 403,524 shares, compared to its average volume of 567,077. Aldeyra Therapeutics, Inc has a 12 month low of $2.71 and a 12 month high of $6.55. The business has a fifty day moving average of $5.17 and a 200 day moving average of $4.69. The company has a debt-to-equity ratio of 0.18, a quick ratio of 6.80 and a current ratio of 6.80.

Aldeyra Therapeutics (NASDAQ:ALDX - Get Free Report) last announced its earnings results on Thursday, November 7th. The biotechnology company reported ($0.25) earnings per share for the quarter, hitting the consensus estimate of ($0.25). As a group, research analysts forecast that Aldeyra Therapeutics, Inc will post -0.92 EPS for the current fiscal year.

About Aldeyra Therapeutics

Aldeyra Therapeutics is a clinical-stage biotechnology company focused on the development of novel therapies with the potential to improve the lives of patients with immune-mediated diseases. Two of the company’s lead compounds, reproxalap and ADX-629, target reactive aldehyde species (RASP), which are elevated in ocular and systemic inflammatory disease, leading to elevated levels of cytokine release via activation of a broad array of inflammatory factors, including NF-κB, inflammasomes, and Scavenger Receptor A.